Alpha-Gal in Medications and Medical Procedures What Patients and Providers Must Know

For patients with alpha-gal syndrome (AGS), the danger does not stop at the dinner plate. AGS "includes both drug allergy, characterized by immediate hypersensitivity responses to injected pharmaceutical products containing alpha-gal, and food allergy" (PMC 2020). The clinical implications reach into operating rooms, infusion suites, vaccine clinics, and pharmacies, because mammal-derived ingredients are woven through the entire pharmacopeia — the full inventory of drugs and medical products in use.

"In addition, multiple medications are derived from mammals and specific mammalian tissues are used as medical devices. Products such as heart valves, gelatin-based plasma expanders, and pancreatic enzymes, are sources of alpha-gal exposure yet may trigger a reaction in more select patient groups." — T&F, 2020. Diagnosis & Management of...

In plain terms: many medicines and medical devices come from animal tissue. Heart valves, gelatin in IV bags, and digestive enzymes are all on the list, but only some patients react to each. The 2020 Commins review frames the scope: "allergen avoidance for patients with AGS can present unique challenges for management" (T&F 2020) precisely because mammal-derived inputs are everywhere in healthcare. "Evidence for the presence of alpha-gal in these different food and medical products varies markedly" (T&F 2020). One product (cetuximab, a cancer drug) is unambiguously dangerous; many others are tolerated by most patients but trigger severe reactions in a few.

This article catalogs what is known about that procedure-level exposure landscape: which drugs, devices, and procedures carry alpha-gal, what the published evidence says about reaction risk, and what AGS patients must tell providers — particularly before surgery. For dietary exposure and home label-reading, see alpha-gal dietary management. For what to do during an actual reaction, see alpha-gal anaphylaxis emergency preparedness.

Can alpha-gal syndrome cause reactions to medications or during surgery?

Yes — and the highest-stakes scenarios are intravascular, meaning the drug enters a vein or artery directly. Commins notes that AGS "can involve immediate reactions to drugs which are delivered intravascularly" (T&F 2020), in contrast to the characteristic 3-to-6-hour delay after eating mammalian products. When alpha-gal goes straight into the bloodstream, the immune system encounters it within minutes rather than hours. CDC's clinical-features review puts the same point more compactly: "Symptom onset is more rapid with intramuscular or intravenous exposures" (CDC 2022).

How often does this matter? A 2024 Psychiatric Times article reports that "half of patients with AGS have had an anaphylactic reaction to a health product" (PsychT 2024), citing a recent patient survey. About one in two — a striking rate for any allergy population.

Cardiac surgery is the setting that has drawn the most concern. The 2025 Macdougall review explains:

"For example, the use of heparin and bioprosthetic heart valves are of particular interest during cardiac surgery. Heparin is used in high doses during cardiopulmonary bypass surgeries to prevent the formation of blood clots; it is derived from bovine lungs and porcine mucosa and has been found to have detectable levels of alpha-gal." — PMC, 2022. The Meat of the Matter: U...

Cardiopulmonary bypass — the heart-lung machine used during open-heart surgery — requires high doses of heparin, a blood-thinner extracted from pig and cow tissue. Bioprosthetic heart valves come from pig or cow hearts. Both routes feed alpha-gal directly into the bloodstream of someone whose immune system may already be primed against it.

The clinical signal in surgical cohorts is striking. In one institutional review:

"In light of this finding, Hawkins et al postulated that patients with AGS would have higher rates of anaphylaxis compared to controls if they received heparin anticoagulation. In their review of over 8800 patients seen at a single institution for cardiac surgery evaluation, they found 17 patients sensitized to alpha-gal, four (24%) of whom underwent cardiac surgery and suffered anaphylactic shock. Among the eight patients with alpha-gal serum IgE levels checked within 90 days of surgery, the rate of anaphylaxis was 50% (four of eight patients)." — PMC, 2022. The Meat of the Matter: U...

Read those numbers carefully: roughly one in four AGS patients who went through cardiac surgery suffered anaphylactic shock — a rate that climbs to one in two among the small group whose alpha-gal antibodies had been measured close to surgery.

A 2025 review of AGS as a hidden and underrecognized condition emphasizes that the cardiac-surgery problem predates the literature on it: "Alpha-gal has always been an issue in cardiac surgery, despite the paucity of literature on the topic." (IJGM 2025) The same review explains: "Some anesthesia products contain mammalian components, and bioprosthetic valves; and even existing bio-prostheses can be retroactively vulnerable if patients acquire AGS." (IJGM 2025) A valve implanted years before an AGS diagnosis can become a problem after the fact: the patient develops AGS from a tick bite, and the animal-derived valve already inside their chest becomes a source of ongoing exposure.

Beyond cardiac surgery, anesthesiology — the medical specialty that manages drugs given before, during, and after surgery — faces its own version of this problem. Macdougall describes the position anesthesiologists are placed in:

"AGS can present challenges for anesthesiologists when selecting anesthetic agents and other perioperative medications as patients are not always identified or clearly labeled as having AGS prior to procedures and it is difficult to determine which medications may contain alpha-gal. In regard to medications, the major concern is inactive ingredients, such as stearic acid, lactic acid, glycerin, and gelatin, rather than the active drug itself. Some inactive ingredients are derived from animal or plant sources; however, this information is not always readily available to be able to identify safe products." — PMC, 2022. The Meat of the Matter: U...

The trap here is that anesthesiologists rarely worry about the active drug; they worry about the inactive ingredients — the fillers, binders, and stabilizers that hold a pill or solution together. Many of those, like glycerin or stearic acid, can come from either an animal or a plant source, and labels usually do not say which.

Intraoperative reactions have been documented to gelatin-based hemostatic agents — surgical sponges and powders that use animal-derived gelatin to stop bleeding: "case reports of intraoperative anaphylaxis to gelatin-based hemostatic agents in patients with AGS" (PMC 2022) — and the Psychiatric Times piece adds another perioperative warning, covering the period right before, during, and after a procedure: "In the operative setting, porcine valves, certain types of sutures, and common drugs including heparin and oxycodone are off-limits." (PsychT 2024)

Even ophthalmology — eye care and eye surgery — is implicated. "Ophthalmology is considered less frequently than most other fields as a route to diagnosis, but AGS has implications even there" (IJGM 2025) — specifically, mammalian-derived corneal grafts, where a donor-tissue replacement for the clear front of the eye may carry alpha-gal.

The throughline across all these settings is that recognition matters more than any single avoidance rule. Vaz Rodrigues and colleagues argue that "it is recommended for AGS-suffering patients to wear warning bracelets about their condition so that physicians are aware and can prevent future life-threatening situations in emergency cases" (PMC 2022). Caron's case-report group puts the patient-side imperative simply: "the patient should inform their physician about AGS before any treatment" (PMC 2022).

That patient-side burden is heavier than it should be because provider knowledge of AGS is not yet routine. One patient told the Tick-Borne Conditions United survey:

""I've been the patient being wheeled into surgery at a major university hospital being told 'You're our first patient with Alpha-Gal, do YOU know if this anesthesia is safe for you?' I had previously spent hours personally researching that very question but that should never be my responsibility." "I was in the hospital 2 weeks ago with anaphylaxis and not one person there, not one, had any idea what I was trying to tell them." — TBCU, 2019, pp. 2–3. Alpha-gal Patient Perspec...

That kind of role-reversal — patient briefing the surgical team on their own anesthesia safety — happens because the workforce has not caught up. The same patient survey found that lack of provider knowledge tops the list of patient-identified concerns, and that "a lack of knowledge about AGS exists across numerous players in the healthcare system including pharmacists, dentists, medical and dental device manufacturers, and emergency medical technicians" (TBCU 2019).

What medications contain alpha-gal that I need to avoid?

There is no master list. The 2023 MDPI review puts the scale of the problem plainly: "More than 20,000 drugs, vaccines, etc., contain mammalian byproducts. It can be challenging to know if any are present in food/medications despite checking labels, because no complete list exists." (MDPI 2023) What follows are the categories that the AGS clinical literature treats as known or suspected sources, organized by exposure type rather than alphabetically.

Cetuximab and other monoclonal antibodies

Cetuximab is the canonical example — the drug whose hypersensitivity pattern led to the discovery of AGS itself. The Macdougall review describes it bluntly:

"Classically, therapy with the chimeric, monoclonal antibody cetuximab, a drug used primarily to treat head and neck and colorectal cancers, can cause severe anaphylaxis and death if administered to patients with AGS. While globally, the immediate hypersensitivity response rate to cetuximab was less than 3%, studies of patients in the southeastern US who received this biological product revealed hypersensitivity reactions as high as 22%." — PMC, 2022. The Meat of the Matter: U...

A monoclonal antibody like cetuximab is a lab-made protein designed to lock onto one specific target in the body — in this case, a receptor on cancer cells. The "chimeric" part means part of the protein is built from mouse cells, which is exactly where the alpha-gal sugar gets attached. The geographic signal that originally tipped researchers off remains visible: "In the southern US, areas with large tick populations have been associated with higher rates of cetuximab anaphylaxis" (PMC 2022). The clinical lesson is one of pre-treatment screening — "the importance of screening for a history of adverse reactions to mammalian meat prior to using cetuximab" (PMC 2022).

Other monoclonal antibodies sit on a spectrum. The Shishido review consolidates the named offenders: "Cetuximab, abatacept, and infliximab each contain AG." (PMC 2025) Abatacept (brand name Orencia) is used for rheumatoid arthritis; infliximab (brand name Remicade) is used for Crohn's disease, ulcerative colitis, and psoriasis. Commins' team confirms "abatacept (Orencia), which is manufactured in a Chinese hamster ovary (CHO) cell line and also shown to contain the alpha-gal epitope" (T&F 2020), and notes infliximab as a milder case: "Another exception is infliximab, which has been shown to express low amounts of the alpha-gal and, despite wide usage, has been linked to only a small number of reactions in patients with AGS." (T&F 2020) Production matters as much as the molecule: Macdougall notes that switching cell lines can solve the problem, since "cetuximab produced by CHO cells had no detectable alpha-gal moieties" (PMC 2022). The same drug grown in mouse cells carries alpha-gal; grown in hamster cells, it does not — a manufacturing choice with allergy stakes.

Heparin

Heparin — a blood-thinner drawn from pig intestines and cow lungs — is everywhere in hospitals, and exposure depends sharply on dose. Commins:

"Heparin: Heparin is derived from pig intestines. A small number of case reports have raised the possibility of heparin-induced allergic reactions in patients with AGS. Importantly, we have not had issues with routine heparin prophylaxis for deep venous thrombosis (DVT) and our experience suggests this can be safely administered for the overwhelming majority of patients with AGS. There are, undoubtedly, exceptions that will require alternate forms of DVT prophylaxis." — T&F, 2020. Diagnosis & Management of...

The phrase to notice is "DVT prophylaxis" — small preventive doses to stop blood clots in the legs, the routine kind given to most hospitalized patients. Those low doses are usually safe in AGS. The dose distinction matters because the high-anticoagulation scenarios are exactly the cardiac procedures already flagged above. Commins continues: "Heparin-based reactions that are much more common include those clinical scenarios where heparin is given at high doses for more complete anti-coagulation, such as during heart catheterization, valve procedures and extracorporeal membrane oxygenation (ECMO)." (T&F 2020) ECMO is a life-support machine that takes over the work of the heart and lungs in critically ill patients and demands very high heparin doses to keep blood from clotting in its tubing. Shishido's 2025 ID-practitioner-focused review reaches the same conclusion: "Larger boluses of heparin used in heart catheterization, valve procedures, or extracorporeal membrane oxygenation are more likely to trigger reactions." (PMC 2025)

When heparin is unavoidable, Commins describes a workable approach: "a standard pre-medication regimen using corticosteroid, antihistamine and even omalizumab has been successful at minimizing reactions to large doses of heparin in our experience" (T&F 2020), with sodium citrate as an alternative anticoagulant for line maintenance. In plain terms: pre-treat with anti-inflammatory steroids and allergy-blocking drugs (the same family as Benadryl), and for keeping IV lines from clotting, switch to a non-mammal alternative.

Bioprosthetic heart valves

Animal-derived heart valves and other implanted bioprosthetics carry alpha-gal. Patel's review describes both sequencing risks: developing AGS after a valve, and getting a valve while already AGS-positive.

"By contrast, another case series showed that porcine or bovine valve replacement in patients with pre-existing alpha-gal syndrome was associated with peri- and postoperative anaphylaxis attributed to the rapid release of residual alpha-gal antigen in bioprosthetic valves, but longer-term tolerance of their valve replacements. Immediate allergic reactions were managed with epinephrine and adjunctive therapies like H1 and H2 blockers and corticosteroids. At 6 to 12 months of followup, they were tolerating their bioprosthetic valves, possibly due to a significant reduction in alpha-gal antigen release from the valve over time." — PMC, 2020. "Doc, Will I Ever Eat St...

The encouraging piece of this finding: the alpha-gal sugar leaches out of the valve over time, so a reaction-prone first year often gives way to long-term tolerance.

The same review documents premature device degeneration:

"Alpha-gal specific IgE has also been linked to two cases of premature bioprosthetic heart valve degeneration in patients who developed alpha-gal syndrome years after their aortic valve replacements. Clinical symptoms, including chest pain and dyspnea, in conjunction with prosthetic valvular insufficiency and degeneration, developed 1–2 years after diagnosis with alpha-gal syndrome, requiring replacement with mechanical prosthetic valves." — PMC, 2020. "Doc, Will I Ever Eat St...

Here the body's immune attack on the alpha-gal in the valve appears to wear the valve out faster than it should — patients ended up needing a second surgery to swap the bioprosthetic for a mechanical (non-animal) valve. Commins' team adds that "Published reports have described patients who experienced hives or even anaphylaxis after transplantation of bovine or porcine heart valves" (T&F 2020), and Macdougall notes broader concerns across implanted materials: "AGS serum reacted strongly to various animal-derived implants including cardiac patches, vascular" (PMC 2022) and other bovine-or-porcine materials.

Gelatin: vaccines, capsules, and IV plasma expanders

Gelatin is one of the most consequential exposures because it is everywhere — and the route of exposure changes the risk. Gelatin is the same animal-derived protein found in marshmallows and Jell-O, but it shows up in medicine as the casing on capsules, a stabilizer in vaccines, and — most dangerously — as a volume-replacement fluid pumped into a vein. The most severe published reactions involve intravenous gelatin: "the most severe anaphylaxis has been seen when gelatin is administered intravenously as a plasma expander" (MDPI 2023). A plasma expander is an IV fluid given to bring blood volume back up after major bleeding or shock — and when it is gelatin-based, it delivers alpha-gal straight into the bloodstream in large quantity. Commins names the same scenario as the worst case for gelatin exposure: "The most severe reactions involving gelatin are anaphylaxis that has been well-documented when gelatin was administered IV as a plasma expander in some countries, particularly Australia and the U.K." (T&F 2020).

Vaccines containing gelatin are a separate category of exposure. Commins flags "Vaccines are also an important source of gelatin exposure, including Zostavax and MMR" (T&F 2020) — Zostavax is the older shingles vaccine, and MMR is the measles-mumps-rubella childhood vaccine. Shishido provides the broader gelatin-vaccine list:

"It is particularly important for the ID practitioner to be aware of the vaccines that contain gelatin, which include live intranasal influenza, measles-mumps-rubella, varicella, oral typhoid, rabies, and yellow fever vaccines . While an analysis of 2684 patients sensitized to AG and 25 patients with AGS found no significantly increased risk of anaphylaxis after receiving vaccines, with and without gelatin, we recommend considering gelatin-free alternatives or assessing safety of these products by skin-prick testing performed by an allergist before administering these vaccines." — PMC, 2025. A Review of Alpha-Gal Syn...

The reassuring footnote in that quote: a study of nearly three thousand alpha-gal-sensitized people did not find a higher rate of anaphylaxis from these vaccines. The published evidence is mixed: Macdougall summarizes that there have been "case reports of individuals with AGS experiencing anaphylaxis following administration of gelatin-containing vaccines and reports of patients with AGS tolerating vaccines with gelatin in the excipients" (PMC 2022), and concludes that gelatin-containing immunizations should be administered with caution.

Gelatin capsules — the casing on many oral medications — sit at the lower end of the risk spectrum. Commins:

"Gelatin capsules (“gel-caps”) are used for many medicines and may give rise to symptoms in a small proportion of patients. This exposure has been an infrequent (<5%) source of heartburn and/or nausea in patients, especially those whose medication regimen make contain multiple gelatin-based capsules." — T&F, 2020. Diagnosis & Management of...

In plain terms: fewer than one in twenty AGS patients gets symptoms from gel-cap medications, and the symptoms tend to be heartburn or nausea rather than full-body reactions.

Antivenoms

Snake antivenoms — emergency drugs given after a venomous bite that contain antibodies harvested from the blood of immunized animals — are typically produced in non-primate mammals and contain alpha-gal. Macdougall summarizes the published evidence:

"However, there are case reports of patients in the southeastern US with anaphylaxis to sheep-derived, crotalidae polyvalent immune Fab antivenom (CroFab) as a first presentation of alpha-gal syndrome. Subsequent reports demonstrated that galactose-alpha-1,3-galactose is detectable in CroFab as well as in equine antivenom and can bind to alpha-gal allergic serum causing degranulation of alpha-gal sensitized basophils." — PMC, 2022. The Meat of the Matter: U...

CroFab is the standard US antivenom for pit-viper bites (rattlesnakes, copperheads, cottonmouths); it is made by immunizing sheep, then collecting and purifying the antibodies. Those sheep antibodies carry alpha-gal. A larger study of 55 patients in Laos found that "alpha-gal IgE was detected in the serum of 17 (31%) of these patients. However, there was no relationship between alpha-gal IgE positivity and development or severity of acute adverse reactions to antivenom" (PMC 2022) — suggesting alpha-gal is one factor among several driving antivenom hypersensitivity rather than the primary driver. Patel's tiered framework (detailed in the next section) places anti-venom in the highest-risk Tier 1 category, but the consequence of an untreated venomous snakebite remains catastrophic, so the calculus sometimes lands differently than the tier alone would suggest.

Pancreatic enzymes and thyroid replacements

Replacement therapies that come from mammalian glands carry alpha-gal directly. Commins explains that "The enzymes used for replacement of pancreatic function (e.g., pancrealipase) are purified from the pancreas of large mammals" (T&F 2020), and that "Supplementation or replacement of endogenous thyroid hormone with ‘natural’ products (e.g., Armour thyroid) may be less ideal in patients with AGS since these products are derived from porcine thyroid glands" (T&F 2020). Pancreatic enzymes are prescribed when the pancreas cannot make enough of the enzymes needed to digest food (a problem in cystic fibrosis and chronic pancreatitis); the standard versions are pulled from pig and cow pancreases. Thyroid hormone replacement is the daily medication for an underactive thyroid; "natural" thyroid products like Armour come from pig thyroid glands, while the more common synthetic version (levothyroxine) is animal-free. The 2023 MDPI review lists the same two as ongoing concerns: "Pancreatic enzyme and thyroxine supplementation can also be fraught with reactions in AGS patients." (MDPI 2023)

Inactive ingredients in oral medications

This is the category most likely to surprise patients and providers, because it cuts across nearly every drug class. The Narlesky case report is the clearest summary:

"Unfortunately, alpha-gal is common in medications because mammalian products, such as magnesium stearate, glycerin, and lactic acid, are often used as inactive ingredients. Lactose alone is used in approximately 45 percent of all tablets and capsules in the United States." — PMC, 2022. Initiating Psychotropic T...

The active drug is whatever the pill is named after — the ibuprofen in an ibuprofen tablet. The excipients are everything else in the tablet: binders that hold the powder together, lubricants that keep it from sticking to the manufacturing equipment, fillers that make it big enough to handle. Those excipients are where the alpha-gal hides. Generic medications routinely contain mammal-derived inactives: "Examples of common generic medications containing mammalian products include hydromorphone, pregabalin, buspirone, and oxycodone, among many others." (PMC 2022) The complication is that the same molecule can come from a plant or an animal source, and "stearic acid and lactic acid are generally alpha-gal positive if sourced from animals and alpha-gal negative if sourced from plants" (PMC 2022), with sourcing not disclosed on labels. Two pills with identical ingredient lists can be safe or dangerous depending on a sourcing decision the manufacturer never has to print.

A 2024 Psychiatric Times piece details how this plays out in psychiatry specifically:

"Gelatin capsules and animal-derived stabilizers, including lactose and other mammalian products, frequently occupy selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants, 1st and 2nd generation antipsychotics, mood stabilizers (lithium, anticonvulsants), and anxiolytic (benzodiazepine and nonbenzodiazepine) medications. These were found just from a cursory glance online, because not even the CDC has a comprehensive list, deferring to the patient’s provider." — PsychT, 2024. Climate Change, Vector Ra...

That list covers nearly every category of psychiatric medication — antidepressants, antipsychotics, mood stabilizers, anti-anxiety drugs — meaning a person with AGS who needs psychiatric care has to vet each prescription individually.

A reassuring counterweight: Patel notes that "the vast majority of patients with alpha-gal syndrome tolerate most orally delivered pharmaceutical products, even those with trace amounts of alpha-gal" (PMC 2020). When a critical drug has no clean alternative, the pathway is "referral to an allergist for an oral challenge with this medication, even in patients with confirmed alpha-gal syndrome and positive skin testing to the drug" (PMC 2020). An oral challenge is a supervised in-office trial of the drug, with emergency treatment on hand, so patient and doctor can see together whether a reaction actually occurs.

How clinicians stratify these exposures

Patel's review proposes a tiered framework that maps directly onto procedure-level decisions. The framework sorts exposures into three groups, from "must avoid" to "watch for in highly sensitive patients." Tier 1 covers the highest-risk products:

"“Tier 1” avoidance involves elimination of dietary beef, pork, lamb, venison and other mammalian meats and innards as well as intravenous medications with high alpha-gal content including cetuximab, gelatin-based colloid agents, and -- after weighing risks and benefits -- anti-venom therapies. We also remind our patients to watch for “hidden sources” of alpha-gal including beef broth in soups, animal fat drippings in gravy, pork encasings for chicken or turkey sausages, or fatback or bacon in vegetable dishes and salads." — PMC, 2020. "Doc, Will I Ever Eat St...

Tier 1, in short: red meat, the highest-content IV drugs, and anti-venom — with anti-venom included on the avoid-if-possible list while acknowledging that an actual snakebite changes the math. Tier 2 escalates to bioprosthetic valves and gelatin-containing vaccines:

"“Tier 2” avoidance includes Tier 1 avoidance plus the elimination of dietary dairy products; avoiding heart valve replacements with bovine or porcine products; and avoiding (if possible), gelatin-containing vaccines (e.g. Zostavax; measles, mumps, and rubella (MMR)). Symptoms resolve in 95% percent of alpha-gal allergic patients with Tier 2 avoidance." — PMC, 2020. "Doc, Will I Ever Eat St...

Most AGS patients (about 95%) become symptom-free at this Tier 2 level — meaning red meat plus dairy plus the above procedure-level avoidances. Tier 3 adds gelcaps, heparin, and pancreatic enzymes — exposures relevant to the most sensitive patients.

Why labeling is the bottleneck

The reason patients carry so much of the burden is that the disclosure infrastructure does not yet exist. The Narlesky case report puts the regulatory state of play directly: "Currently, pharmaceutical companies are not required to list the presence of alpha-gal content or the mass of excipients" (PMC 2022), and "As generic manufacturers often use different ingredients for the same medication, it is not feasible to generalize the alpha-gal content of one drug formulation to other formulations." (PMC 2022) The FDA's Inactive Ingredient Database is one partial response — a public list of which inactive ingredients are present in approved drugs — but it does not solve animal-versus-plant sourcing.

When patients try to fill the gap themselves, they hit a wall. The 2023 MDPI review reports that "Up to 20% of AGS patients have contacted drug manufacturers asking about the ingredients more than 10 times. Only about 60% of the pharmaceutical companies provide an accurate response about mammalian-derived medication ingredients." (MDPI 2023) Even after ten phone calls, four out of ten patients still cannot get a straight answer about what is in their medication. The Psychiatric Times article describes the same finding from the manufacturer side: "Of the top 20 pharmaceutical companies, only 60% were able to accurately provide information on whether there were animal products in their formulation." (PsychT 2024)

The burden of mismatched labeling is a top-line patient concern. The 2019 Tick-Borne Conditions United survey ranked patient priorities; ingredient labeling came second only to provider awareness:

"• 89% Lack of healthcare provider knowledge • 79% Ingredient labeling on food and pharmaceuticals • 36% Funding for additional research on Alpha-gal • 35% Other • 21% Lack of non-mammal ingredient vaccinations • 21% Broader tick testing to capture additional conditions • 15% Need for treatment, prevention, and signage in public places • 8% Coping in the workplace and school environment • 5% Mammal-free tick repellents and yard treatments • 5% Lack of understanding and support from family" — TBCU, 2019, pp. 2–3. Alpha-gal Patient Perspec...

Patient advocacy has moved on this — "More than 1400 patients with AGS have petitioned the FDA to require drug manufacturers to clearly label whether ingredients used in their products are mammalian derived." (MDPI 2023) The Psychiatric Times piece argues for the same fix: "Mandated reporting of all drug ingredients would go a long way in managing their care and alleviating stress for both patients and their providers." (PsychT 2024) Until that happens, Commins captures the structural problem in a sentence: "For patients with AGS, however, this tenet of self-protection is made difficult by the lack of adequate labeling for mammalian-derived sources in foods, medications, and vaccines." (T&F 2020)

A future of alpha-gal-free medical products is in development. In December 2020, the FDA approved "a genetically altered line of pigs known as “Gal-Safe Pigs” to generate medical products and to use as a potential human food source" (PMC 2022), engineered to lack the enzyme that builds the alpha-gal sugar. Commins frames the destination: "Approval of alpha-gal free porcine products would represent an effective way to develop ‘AGS-safe’ foods, medications, and implantable devices." (T&F 2020) Until those products reach the bedside, what AGS patients can do is the same thing patients have done since the disorder was named: tell every provider, before every procedure, every time.

Sources

    Not medical advice. See a healthcare provider for medical decisions. Medical Disclaimer